Adcetris (Brentuximab Vedotin) Patent Expiration, LOE Window & CMS Spending

Adcetris (Brentuximab Vedotin) by Pfizer: Biologic BLA (Purple Book Regime), 0 AB generics, $96.0M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayB125388 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$96.0M
2024 Medicare Part D Spend$3.5M
2024 Medicaid Spend$92.4M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 26.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.